X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA JUBILANT LIFE SCIENCES DISHMAN PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 25.1 17.8 140.8% View Chart
P/BV x 3.3 4.7 71.4% View Chart
Dividend Yield % 0.7 0.4 171.2%  

Financials

 DISHMAN PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
JUBILANT LIFE SCIENCES
Mar-14
DISHMAN PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs374187 200.4%   
Low Rs12965 198.0%   
Sales per share (Unadj.) Rs197.8364.3 54.3%  
Earnings per share (Unadj.) Rs21.26.8 309.8%  
Cash flow per share (Unadj.) Rs34.724.5 141.7%  
Dividends per share (Unadj.) Rs2.003.00 66.7%  
Dividend yield (eoy) %0.82.4 33.4%  
Book value per share (Unadj.) Rs179.9164.9 109.1%  
Shares outstanding (eoy) m80.69159.28 50.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.3 368.0%   
Avg P/E ratio x11.918.4 64.5%  
P/CF ratio (eoy) x7.25.1 141.0%  
Price / Book Value ratio x1.40.8 183.1%  
Dividend payout %9.443.8 21.5%   
Avg Mkt Cap Rs m20,30620,061 101.2%   
No. of employees `0000.86.2 13.4%   
Total wages/salary Rs m5,35511,052 48.5%   
Avg. sales/employee Rs Th19,252.79,383.0 205.2%   
Avg. wages/employee Rs Th6,459.51,786.9 361.5%   
Avg. net profit/employee Rs Th2,064.1176.3 1,170.8%   
INCOME DATA
Net Sales Rs m15,96158,034 27.5%  
Other income Rs m265191 139.2%   
Total revenues Rs m16,22658,224 27.9%   
Gross profit Rs m4,1035,786 70.9%  
Depreciation Rs m1,0912,812 38.8%   
Interest Rs m9443,237 29.2%   
Profit before tax Rs m2,334-72 -3,236.6%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m624696 89.5%   
Profit after tax Rs m1,7111,090 156.9%  
Gross profit margin %25.710.0 257.8%  
Effective tax rate %26.7-965.9 -2.8%   
Net profit margin %10.71.9 570.6%  
BALANCE SHEET DATA
Current assets Rs m11,01829,280 37.6%   
Current liabilities Rs m9,51738,912 24.5%   
Net working cap to sales %9.4-16.6 -56.7%  
Current ratio x1.20.8 153.9%  
Inventory Days Days11084 131.0%  
Debtors Days Days3551 68.7%  
Net fixed assets Rs m16,30455,712 29.3%   
Share capital Rs m161155 104.5%   
"Free" reserves Rs m12,90720,968 61.6%   
Net worth Rs m14,51626,265 55.3%   
Long term debt Rs m4,18917,169 24.4%   
Total assets Rs m29,80588,606 33.6%  
Interest coverage x3.51.0 355.0%   
Debt to equity ratio x0.30.7 44.2%  
Sales to assets ratio x0.50.7 81.8%   
Return on assets %8.94.9 182.4%  
Return on equity %11.84.2 283.9%  
Return on capital %17.511.6 151.6%  
Exports to sales %24.837.8 65.6%   
Imports to sales %3.716.5 22.7%   
Exports (fob) Rs m3,95621,933 18.0%   
Imports (cif) Rs m5969,567 6.2%   
Fx inflow Rs m4,95222,004 22.5%   
Fx outflow Rs m69711,749 5.9%   
Net fx Rs m4,25510,255 41.5%   
CASH FLOW
From Operations Rs m2,7868,026 34.7%  
From Investments Rs m-1,529-1,744 87.7%  
From Financial Activity Rs m-941-4,447 21.2%  
Net Cashflow Rs m3161,834 17.2%  

Share Holding

Indian Promoters % 61.4 45.6 134.6%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 3.7 8.7 42.5%  
FIIs % 12.7 21.2 59.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 21.1 104.7%  
Shareholders   46,261 23,815 194.3%  
Pledged promoter(s) holding % 35.8 15.9 225.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, BOB-Vijaya-Dena Merger, and Top Stocks in Action Today(Pre-Open)

Share markets in India continued their momentum and ended in red yesterday. Sectoral indices traded in red, with stocks in the realty sector, power sector and PSU sector leading the losses.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS